As a potential therapy, B7-H5 blockade suppressed tumor growth by enhancing the infiltration, proliferation, and effector function of T cells, and reducing B7-H5+ MDSCs and Tregs.273,278 Anti-B7-H5 mAb HMBD-002 and onvatilimab, and small molecule inhibitor CA-170 have entered clinical trials (Table 1 and Supplementary Table 1). The gene discussed is CD80; the disease is neoplasm.